middle.news
SomnoMed CEO Steps Down as FY26 Revenue Misses Guidance and New Product Launch Begins
6:39pm on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
SomnoMed CEO Steps Down as FY26 Revenue Misses Guidance and New Product Launch Begins
6:39pm on Monday 27th of July, 2026 AEST
Key Points
Co-CEO Amrita Blickstead resigns, Karen Borg becomes sole CEO
Preliminary FY26 revenue $114-115 million below $119-126 million guidance
EBITDA mid-range at $10-12 million supported by cost discipline
European market challenges slow patient uptake due to reimbursement changes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Somnomed (ASX:SOM)
OPEN ARTICLE